Immune Design to Report Second Quarter 2017 Financial Results & Provide Corporate Update
July 26 2017 - 8:00AM
Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company
focused on cancer, today announced that it will report second
quarter 2017 financial results and provide a corporate update after
the close of U.S. financial markets on Wednesday, August 2, 2017.
Immune Design management will host a webcast and conference call at
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 2, 2017.
The live call may be accessed by dialing 844-266-9538 for
domestic callers and 216-562-0391 for international callers. A live
webcast of the call will be available online from the investor
relations section of the company website at
http://ir.immunedesign.com/events.cfm and will be archived there
for 30 days. A telephone replay of the call will be available for
five days by dialing 855-859-2056 for domestic callers or
404-537-3406 for international callers and entering the conference
code: 58230231.
About Immune Design
Immune Design is a clinical-stage immunotherapy
company employing next-generation in vivo approaches to enable the
body's immune system to fight disease. The company's technologies
are engineered to activate the immune system's natural ability to
generate and/or expand antigen-specific cytotoxic T cells, while
also enhancing other immune effectors, to fight cancer and other
chronic diseases. CMB305 and G100, the primary foci of Immune
Design's ongoing immuno-oncology clinical programs, are products of
its two synergistic discovery platforms, ZVex® and GLAAS®. Immune
Design has offices in Seattle and South San Francisco. For more
information, visit www.immunedesign.com.
Media Contact
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219
Investor Contact
Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Sep 2023 to Sep 2024